Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis

NCT02542787 is registered in ClinicalTrials.gov with Canbex Therapeutics Ltd as lead sponsor.

NCT NCT02542787
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02542787 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis
Lead sponsor
Canbex Therapeutics Ltd
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2015
Completion date
October 31, 2017
Enrollment
160 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

spasticity in people with multiple sclerosis